Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 17.59m |
Free float | 17.19m |
P/E (TTM) | -- |
Market cap | 388.32m USD |
EPS (TTM) | -0.8136 USD |
Data delayed at least 15 minutes.
More ▼
Press releases
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
- Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
- Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel to Present at the 2024 Cantor Global Healthcare Conference
- Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
- Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
- Rigel to Participate in Upcoming September Investor Conferences
More ▼